Loading...

ACLX ARCELLX INC Expansion Plans 8-K Filing

RCLL

CLX

ARCELLX INC

(ACLX)

2025 8-K

Merger Announcement

Positive Clinical Data

Financial Results Update

Earnings Releases

Product Expansion

Financial Statements

Financial Results

Investor Webcast

Positive Study Results

Financial Results

Clinical Data Release

Financial Results Announcement

Annual Meeting of Stockholders

Earnings Reports

Dismissal and Appointment o...

Earnings Reports

Termination of Lease Agreement

Stock Purchase Agreement

Webcast Investor Relations ...

Clinical Data Announcement

Amendment to Collaboration ...

Financial Results Announcement

Clinical Data Release

Financial Results Announcement

Other Special Situation

Annual Meeting of Stockholders

Equity Offering

Results of Operations and F...

Financial Results and Annua...

Collaboration Agreement and...

External Links:

On May 14, 2025, Arcellx, Inc. announced positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel for treating multiple myeloma, based on results from a data cut on May 1, 2025, and will present updated data at the EHA 2025 Congress on June 14, 2025.

AI Assistant

ARCELLX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.